Search Site
Home >> Research Area >>Nature Products >> 1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone
1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone

1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone

Catalog No. BCN1548
Size Price Stock
20mg $298 In stock
Related Products

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris

Quality Control of 1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone

Chemical structure

1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone

1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties of 1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone

Cas No. 160623-47-2 SDF Download SDF
SMILES CC(=CCc1cc2c(=O)c3c(ccc(c3oc2c(c1O)OC)O)O)C
Standard InChIKey XOFZQNNUVXEIJS-UHFFFAOYSA-N
Standard InChI InChI=1S/C19H18O6/c1-9(2)4-5-10-8-11-16(23)14-12(20)6-7-13(21)18(14)25-17(11)19(24-3)15(10)22/h4,6-8,20-22H,5H2,1-3H3
Type of Compound Xanthones Appearance Yellow powder
Formula C19H18O6 M.Wt 342.4
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other courier with RT , or blue ice upon request.

Preparing Stock Solutions of 1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.9206 mL 14.6028 mL 29.2056 mL 58.4112 mL 73.014 mL
5 mM 0.5841 mL 2.9206 mL 5.8411 mL 11.6822 mL 14.6028 mL
10 mM 0.2921 mL 1.4603 mL 2.9206 mL 5.8411 mL 7.3014 mL
50 mM 0.0584 mL 0.2921 mL 0.5841 mL 1.1682 mL 1.4603 mL
100 mM 0.0292 mL 0.146 mL 0.2921 mL 0.5841 mL 0.7301 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Preparation of 1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone

This product is isolated and purified from the herbs of Garcinia xanthochymus

References on 1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone

Novel substrates for the automated and manual assay of endo-1,4-β-xylanase.[Pubmed: 28384512]


endo-1,4-β-Xylanase (EC 3.2.1.8) is employed across a broad range of industries including animal feed, brewing, baking, biofuels, detergents and pulp (paper). Despite its importance, a rapid, reliable, reproducible, automatable assay for this enzyme that is based on the use of a chemically defined substrate has not been described to date. Reported herein is a new enzyme coupled assay procedure, termed the XylX6 assay, that employs a novel substrate, namely 4,6-O-(3-ketobutylidene)-4-nitrophenyl-β-45-O-glucosyl-xylopentaoside. The development of the substrate and associated assay is discussed here and the relationship between the activity values obtained with the XylX6 assay versus traditional reducing sugar assays and its specificity and reproducibility were thoroughly investigated.

Drug Conversation: How to Talk to Your Child About Drugs Owen Bowden-Jones London: Royal College of Psychiatrists, 2016 ISBN: 978-1-9097265-7-4, 168 pp. Paperback. Price: $38.95 (Book available to purchase in Australia from Footprint Books).[Pubmed: 28383158]




Fatty acid-binding protein 4 regulates fatty infiltration after rotator cuff tear by hypoxia-inducible factor 1 in mice.[Pubmed: 28382782]


Fatty infiltration in skeletal muscle is directly linked to loss of muscle strength and is associated with various adverse physical outcomes such as muscle atrophy, inflammation, insulin resistance, mobility impairments, and even mortality in the elderly. Aging, mechanical unloading, muscle injury, and hormonal imbalance are main causes of muscle fat accumulation, and the fat cells are derived from muscle stem cells via adipogenic differentiation. However, the pathogenesis and molecular mechanisms of fatty infiltration in muscles are still not fully defined. Fatty acid-binding protein 4 (FABP4) is a carrier protein for fatty acids and is involved in fatty acid uptake, transport, and lipid metabolism. Rotator cuff tear (RCT) usually occurs in the elderly and is closely related with fatty infiltration in injured muscle. To investigate potential mechanisms for fatty infiltration other than adipogenic differentiation of muscle stem cells, we examined the role of FABP4 in muscle fatty infiltration in an RCT mouse model.

Structural and Functional State of Erythrocyte Membranes in Mice at Different Stages of Experimental Parkinson's Disease Induced by Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP).[Pubmed: 28382410]


We studied some structural and functional parameters of erythrocyte membranes in mice at the late presymptomatic and early symptomatic stages of experimental Parkinson's disease induced by administration of MPTP (hemolysis, microviscosity of different regions of the lipid bilayer, LPO intensity, activity of antioxidant enzymes, and kinetic properties of acetylcholinesterase). At the presymptomatic stage, significant deviations of the studied parameters from the normal were observed; they were similar in direction and magnitude to those in humans with Parkinson's disease. At the early symptomatic stage, most parameters tended to normal. Microviscosity of bulk lipids increased at the presymptomatic stage and decreased after appearance of clinical symptoms. This dynamics probably reflects activation of compensatory mechanisms aimed at inhibition of oxidative stress triggered by the development of the pathological process.

Kewords:

1,4,6-Trihydroxy-5-methoxy-7-prenylxanthone ,160623-47-2,Nature Products, supplier, inhibitor,Antagonist,Blocker,Modulator,Agonist, activators, activates, potent, BioCrick

Online Inquiry

Fill out the information below

* Required Fields

CheckCode: